Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.26M Buy
343,130
+305,997
+824% +$8M 0.1% 341
2026
Q1
$1.04M Buy
37,133
+19,463
+110% +$518K 0.02% 858
2025
Q4
$440K Sell
17,670
-233,035
-93% -$5.88M 0.01% 963
2025
Q3
$6.39M Buy
250,705
+1,526
+0.6% +$37.7K 0.11% 335
2025
Q2
$6.04M Buy
249,179
+144,751
+139% +$3.38M 0.13% 269
2025
Q1
$2.65M Buy
+104,428
New +$2.73M 0.07% 513
2022
Q4
Sell
-27,071
Closed -$1.19M 1244
2022
Q3
$1.19M Buy
27,071
+17,833
+193% +$867K 0.07% 468
2022
Q2
$484K Buy
+9,238
New +$471K 0.04% 775

Other funds holding PFE

Algert Global's PFE Position: Q2 2026 in Review

Algert Global increased its Pfizer (PFE) stake by 824% in Q2 2026, buying an estimated $8M and bringing the position to 343,130 shares worth $8.26M. The position accounts for 0.1% of the portfolio, ranked #341.

Algert Global first reported a position in PFE in Q2 2022 and has held it in 8 quarters since. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Algert Global held 343,130 shares of Pfizer worth $8.26M as of Q2 2026.
  • Algert Global bought 305,997 Pfizer shares in Q2 2026, an estimated $8M.
  • Pfizer made up 0.1% of Algert Global's portfolio in Q2 2026, its #341 holding.
  • Algert Global first reported a position in Pfizer in Q2 2022 and has held it in 8 quarters since.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.